SCHEDULE: Logos Global Discloses 3% Stake in Tenax Therapeutics

Logos Global Management LP and affiliated entities have filed a Schedule 13G reporting a 3% beneficial ownership stake in Tenax Therapeutics, Inc.

Summary

• Logos Global Management LP, along with its affiliates and Arsani William, reported beneficial ownership of 800,000 shares of Tenax Therapeutics, Inc. common stock.
• The reported stake represents 3.0% of the company's total outstanding common stock, based on 26,525,159 shares outstanding as of May 8, 2026.
• The reporting persons share voting and dispositive power over the 800,000 shares.
• The filing confirms the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine regulatory disclosure of an existing passive investment position.

Positives

• Institutional investment interest from Logos Global Management LP indicates external confidence in the company's equity.
• The filing confirms the investment is passive in nature, suggesting no immediate activist pressure on management.

Negatives

• The stake is below the 5% threshold that typically triggers significant influence or control-related disclosures.

Risks

• The investment is subject to market volatility inherent in the biotechnology sector.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest, which is standard but highlights the nature of fund-based holdings.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's business operations, as it is a standard ownership disclosure.

Management Comments

• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory requirements for institutional investors. This disclosure reflects typical portfolio management activity within the small-cap biotechnology sector, where institutional accumulation is often monitored for signals of long-term conviction.

Comparison to Industry Standards

• The 3% ownership level is a standard position size for institutional funds in small-cap biotech companies.
• The filing adheres to standard SEC requirements for passive investment disclosures.

Stakeholder Impact

• Shareholders may view the presence of an institutional investor as a sign of market interest in the company's equity.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Keywords

Tenax Therapeutics, TENX, Schedule 13G, Institutional Ownership, Logos Global Management, Biotechnology, Equity Disclosure